{{vm.title}}
25{{vm.includesText}}
{{item}}
{{vm.selectText}}
{{ vm.welcomeLabel.trim() }},
{{ vm.userName }}
{{ vm.text }}
{{vm.newUser1}} {{vm.newUser2}} {{vm.newUser3}} {{vm.newUser4}}
{{ vm.unknownUser }}
{{ vm.title }}
{{ vm.title }}
{{ vm.title }}
- {{ vm.siteSelectorList.flyout.cell1.heading }} {{ site.countryLocale }} {{ vm.siteSelectorList.flyout.cell1.global.countryLocale }}
{{ vm.closeTabLabel }}
- {{ vm.flyout.cell2.title }} {{ vm.flyout.cell2.newTabAllow }} {{ vm.flyout.cell2.title }}
- {{ vm.flyout.cell3.title }} {{ vm.flyout.cell3.newTabAllow }} {{ vm.flyout.cell3.title }}
- {{ vm.flyout.cell1.viewAll.label }} {{ vm.flyout.cell1.viewAll.newTabAllow }} {{ vm.flyout.cell1.viewAll.label }}
Register for the KPMG Deal Capsule Newsletter
Register for the KPMG Deal Capsule Newsletter
Stay well informed about transactions in the global life sciences and chemicals industry
Preview of the KPMG Deal Capsule Newsletter
The new edition of our quarterly newsletter on transactions in the global life sciences and chemicals industry, glances back at the significant deals that took place in Q1 2020.
M&A activity visibly cools down in both sectors. Clearly, the global spread of Covid-19 impacted life sciences and chemicals deal activity in the second half of Q1 2020.
- With only one blockbuster deal, life sciences M&A activity was dominated by small- and mid-cap deals.
- With only two large deals above 1 billion US dollars, chemicals M&A activity additionally suffers from ongoing trade conflict between China and the US.
Register here:
© 2020 KPMG AG Wirtschaftsprüfungsgesellschaft, ein Mitglied des KPMG-Netzwerks unabhängiger Mitgliedsfirmen, die KPMG International Cooperative (“KPMG International”), einer juristischen Person schweizerischen Rechts, angeschlossen sind. Alle Rechte vorbehalten.
